Wednesday, June 10, 2026

biotech Β· Essential Tremor Β· Systemic Lupus Erythematosus

Chongqing Precision Biotech

Chongqing Precision Biotech clinical programs β€” 15 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

ι‡εΊ†εΈ‚εˆ›δΈšε€§ι“ι«˜η§‘εˆ›δΈšε›­Aζ ‹, Chongqing, CN HQ
2016 Founded
5 Employees
NMPA registrant Type
Company details
Status
Public
HQ
ι‡εΊ†εΈ‚εˆ›δΈšε€§ι“ι«˜η§‘εˆ›δΈšε›­Aζ ‹, Chongqing, CN
Founded
2016
Employees
5
Programs
109
Drugs
57
Patents
158
Intelligence Β· Clinical Programs

Chongqing Precision Biotech projects

15 ClinicalTrials.gov programs sponsored by Chongqing Precision Biotech.

Chongqing Precision Biotech has 15 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. 1.0mg/kg/day PRAX-562

    Chongqing Precision Biotech Co., Ltd

    Developmental and Epileptic Encephalopathy 1

    phase 3 small molecule active

    1 trial
  2. 18F fluciclovine

    Chongqing Precision Biotech Co., Ltd

    Brain Metastases

    phase 3 small molecule completed

    2 trials
  3. 1mg elsunersen

    Chongqing Precision Biotech Co., Ltd

    Epileptic Encephalopathy

    phase 3 small molecule active

    1 trial
  4. 20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks

    Chongqing Precision Biotech Co., Ltd

    Focal Seizure

    phase 3 small molecule active

    1 trial
  5. 40 mg/day vormatrogine for 12 weeks

    Chongqing Precision Biotech Co., Ltd

    Focal Epilepsy

    phase 3 small molecule active

    1 trial
  6. 60 mg ulixacaltamide

    Chongqing Precision Biotech Co., Ltd

    Essential Tremor

    phase 3 small molecule active

    1 trial
  7. Early Vasopressin

    Chongqing Precision Biotech Co., Ltd

    Septic Shock

    phase 3 small molecule active

    1 trial
  8. ICT-107

    Chongqing Precision Biotech Co., Ltd

    Glioblastoma Multiforme

    phase 3 mab completed

    2 trials
  9. PRAX-114

    Chongqing Precision Biotech Co., Ltd

    Major Depressive Disorder

    phase 3 small molecule completed

    1 trial
  10. PRAX-222

    Chongqing Precision Biotech Co., Ltd

    Voltage-gated sodium channel type II alpha subunit (SCN2A) developmental and epileptic encephalopathy (DEE)

    phase 3 small molecule active

    1 trial
  11. PRAX-562

    Chongqing Precision Biotech Co., Ltd

    SCN2A Encephalopathy

    phase 3 small molecule active

    1 trial
  12. PRAX-628-322

    Chongqing Precision Biotech Co., Ltd

    Focal Epilepsy

    phase 3 small molecule active

    1 trial
  13. PRAX-628-323

    Chongqing Precision Biotech Co., Ltd

    Focal onset seizures or primary generalized tonic-clonic seizures.

    phase 3 small molecule active

    1 trial
  14. Placebo for PRAX-628, PRAX-628

    Chongqing Precision Biotech Co., Ltd

    Focal Epilepsy

    phase 3 small molecule active

    1 trial
  15. vormatrogine

    Chongqing Precision Biotech Co., Ltd

    Epilepsy, Tonic-Clonic

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Chongqing Precision Biotech have?

15 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.